**Background**
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor deficits and non-motor symptoms. The regulation of cholinergic transmission plays a critical role in the pathophysiology of this disease, making the modulation of cholinesterase enzymes a significant area of therapeutic research. Specifically, the balance between acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity is often altered in neurodegenerative states. Targeting BChE selectively can provide a means to modulate neurotransmission and alleviate associated symptoms, such as neuropathic pain and thermal hyperalgesia. In this context, we will introduce a potent and selective BChE inhibitor – Ethopropazine.
**Definition**
Ethopropazine hydrochloride is a potent and selective BChE inhibitor that also acts as a non-selective mAChR and NMDA antagonist, while exhibiting poor AChE inhibitory activity. According to the Ethopropazine technical information, this compound possesses anticholinergic, antihistamine, and antiadrenergic properties.
**In Vitro and In Vivo Studies**
The Ethopropazine biological activity has been extensively evaluated across various models. In vitro studies demonstrated that Ethopropazine (0-250 µM, 24 h) exhibits dose-dependent toxicity in LAN-5 cells with an LD50 of 28 µM. Conversely, at concentrations below 28 µM for 24 hours, it exhibits proliferative properties in SK-N-SH cells by enhancing [3H] thymidine uptake. Furthermore, Ethopropazine (10 μM, 24 h) significantly enhances the proliferation of NCI-H69 cells, an effect that is significantly inhibited by the mAChR3 antagonist 4-DAMP.
Regarding Ethopropazine in vivo efficacy, research using adult female Sprague-Dawley rats with loose ligation of the right sciatic nerve to induce thermal hyperalgesia showed that Ethopropazine (10-30 mg/kg, subcutaneous administration, single dose) can alleviate neuropathic pain in a dose-dependent manner. Specifically, a dose of 20 mg/kg significantly increased paw withdrawal latency (PWL) in the ligated limb at 1 hour post-administration, while 30 mg/kg increased PWL at 1, 2, and 3 hours. Additionally, combining Ethopropazine with α2 agonists such as Clonidine (0.025 mg/kg) or Guanabenz (0.1 mg/kg) enhanced the analgesic efficacy while maintaining safety. In conclusion, Ethopropazine is a selective BChE inhibitor and multi-receptor antagonist with significant potential for research into Parkinson’s disease and neuropathic pain.
Keywords
Ethopropazine, 1094-08-2, Isothazine, Cholinesterase (ChE), iGluR, mAChR, Ionotropic glutamate receptors, Muscarinic acetylcholine receptor, Ethopropazine (Isothazine) hydrochloride, Parkinson’s disease, Cholinesterase, hyperalgesia, Inhibitor, inhibitor, inhibit
References
[1] Giladi N, et al. Toxicity of the specific antimuscarinic agent methoctramine and other non-specific anticholinergic drugs in human neuroblastoma cell lines in vitro. Toxicol In Vitro. 1993 Sep;7(5):595-603.
[2] Inazu M, et al. Functional expression of choline transporter-like protein 1 (CTL1) in small cell lung carcinoma cells: a target molecule for lung cancer therapy. Pharmacol Res. 2013 Oct;76:119-31.
[3] Jevtovic-Todorovic V, et al. Anti-parkinsonian agents procyclidine and ethopropazine alleviate thermal hyperalgesia in neuropathic rats. Neuropharmacology. 2003 May;44(6):739-48.
[4] Sinko G, et al. Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers. Biochimie. 2011 Oct;93(10):1797-807.
[5] V. Debbeti, et al. Transition Metal Complexes of Ethopropazine: Synthesis and Characterization